Showing results (51-60 of 77) with videos related to

Sort By:
Pageof 8
International Journal of Pharmaceutics|October 25, 2019
Prilling of API/fatty acid suspensions: Processability and characterisationE De Coninck, V Vanhoorne, A Elmahdy, et al.
Gut|January 14, 2005
Epithelioid granulomas, pattern recognition receptors, and phenotypes of Crohn's diseaseM Pierik, G De Hertogh, S Vermeire, et al.
Alimentary Pharmacology & Therapeutics|July 14, 2005
The impact of major depressive disorder on the short- and long-term outcome of Crohn's disease treatment with infliximabP Persoons, S Vermeire, K Demyttenaere, et al.
Alimentary Pharmacology & Therapeutics|December 12, 2017
Anti-infliximab antibody concentrations can guide treatment intensification in patients with Crohn's disease who lose clinical responseE Dreesen, T Van Stappen, V Ballet, et al.
Alimentary Pharmacology & Therapeutics|July 22, 2014
Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitisD Wolf, G D'Haens, W J Sandborn, et al.
Gut|April 26, 2008
JC viral loads in patients with Crohn's disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy?J Verbeeck, G Van Assche, J Ryding, et al.
Alimentary Pharmacology & Therapeutics|March 27, 2004
The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort studyL Marchal, G D'Haens, G Van Assche, et al.
Alimentary Pharmacology & Therapeutics|April 4, 2001
Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's diseaseF Cornillie, D Shealy, G D'Haens, et al.
Clinical and Experimental Immunology|January 24, 2004
Involvement of interleukin 18 in Crohn's disease: evidence from in vitro analysis of human gut inflammatory cells and from experimental colitis modelsP Maerten, C Shen, S Colpaert, et al.
Gut|March 2, 2006
Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's diseaseD W Hommes, T L Mikhajlova, S Stoinov, et al.
Pageof 8